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Antipsychotic drugs and metabolic disorders
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NCEP-ATP III: The Metabolic Syndrome: Diagnosis is
established when at least 3 of these risk factors are present
The presence of Metabolic Syndrome increases the risk of
Cardiovascular Disease death by 2,5-fold to 3,5-fold in
comparison to subjects without the syndrome.
The prevalence of Metabolic Syndrome in general popula-
tion is 24% and in untreated patients with Schizophrenia
37%. Patients with schizophrenia or bipolar disorders
tend to be obese or have type-2 diabetes even before the
administration of antipsychotics. Moreover, conventional
antipsychotics and some atypical antipsychotics increase
the trend for obesity or type-2 diabetes, because of their
adverse effect on glucose and lipid metabolism.
Today, accumulated knowledge and advances in pharma-
cology permit safe and effective treatment of psychosis,
related with improvement in several clinically significant
health factors (beneficial effects on metabolic parameters
and body weight). This could significantly reduce the
prevalence of Metabolic Syndrome in patients with schiz-
ophrenia or bipolar disorders and consequently may
diminish the associated Cardiovascular Disease risk.
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Annals of General Psychiatry 2006, 5:S9Table 1: 
Risk Factor Defining Level
1. Abdominal obesity (Waist circumference)
Men >102 cm (>40 in)
Women >88 cm (>35 in)
2. TG3. HDL-C ≥150 mg/dl
Men <40 mg/dl
Women <50 mg/dl
4. Blood pressure ≥130/≥85 mmHg
5. Fasting glucose ≥110 mg/dlPage 2 of 2
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